ImmunoPrecise Antibodies Ltd. Sustainability Profile
ImmunoPrecise Antibodies Ltd., often referred to as IPA, is a leading biotechnology company headquartered in Canada. Founded in 2010, the company has established itself as a key player in the field of antibody discovery and development, with significant operations across North America and Europe. Specialising in custom monoclonal antibodies, ImmunoPrecise offers a unique suite of services, including hybridoma development and phage display technologies, which set them apart in the competitive landscape. The company has achieved notable milestones, such as the successful launch of its proprietary antibody discovery platform, enhancing its market position. With a commitment to innovation and quality, ImmunoPrecise Antibodies Ltd. continues to support the biopharmaceutical industry, providing essential tools for research and therapeutic development.
DitchCarbon Score
How does ImmunoPrecise Antibodies Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ImmunoPrecise Antibodies Ltd.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ImmunoPrecise Antibodies Ltd.'s reported carbon emissions
ImmunoPrecise Antibodies Ltd., headquartered in Canada, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. As there are no emissions data or reduction initiatives available, it is important to note that the company may still be in the early stages of developing its climate strategy. In the broader context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting Science-Based Targets (SBTi) to align with global climate goals. However, without specific commitments or data from ImmunoPrecise Antibodies Ltd., it is unclear how they plan to address climate change or carbon emissions in the future.
How Carbon Intensive is ImmunoPrecise Antibodies Ltd.'s Industry?
How Carbon Intensive is ImmunoPrecise Antibodies Ltd.'s Location?
ImmunoPrecise Antibodies Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ImmunoPrecise Antibodies Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
